RE:RE:RE:Beyond the BCG-unresponsive market Hi Infinity....
I don't know a lot about this particular local irradiation treatment, but from what I can gather it is reported to be prostate-specific via its binding to PSMA (prostate-specific membrane antigen....a transmembrane protein found in prostate cancer cells). However, as you implied, PSMA is found in other types of cancer cell tissues, including bladder cancer/NMIBC as demonstrated in prior studies. However, it isn't clear to me if the amount/intensity of PSMA expression is high enough in bladder cancer/NMIBC for this type of treatment to be effective. That is, the clinical utility of PSMA may be confined to the above form of prostate cancer. Additionally, PSMA is also expressed in healthy bladder tissue (though at a different level), & there would likely be risk to healthy bladder tissue while the drug is being cleared from your body post treatment....in other words, drink plenty of water for a few days.
So, this form of treatment does not come without its systemic/radiation-exposure side effects (including bone marrow suppression)...it is given systemically/IV in multiple doses (I believe 6 doses). And per Pluvicto's safety precautions, once you've been treated, you must also take radiation-exposure precautions. There are recommended human/household contact limitations ranging from 2 to 15 days depending on individual circumstances.
Pluvicto's use for our indication would obviously require years of additional study/clinical trialing, & considering its mechanism of action, side effects & requisite precautions, I don't see this being serious competition anytime soon, if ever (especially if being considered as a single-agent option). All imo. Good luck...